Medivation announced a couple quarters ago that they were going to have an R&D meeting for investors this year. They haven't mentioned it since and we have 2 months left in the year.
You forgot the 100% guarantee it will retrace to $60 and 90% chance it will go to $7, etc
I believe management will revisit the MCC decision about moving it forward. If data is compelling would be silly not to get the product to market where there is no competition.
It was my understanding that ITEK has a more beneficial side effect profile so even if efficacy is similar patients would prefer to not have blood shot eyes
Don't worry. Shorts only make up less than 1% of the float. I just think they're all on this board. haha
Investors need to become familiar with the company. Stock barely trades 100k shares a day so obviously awareness is not there.
With no side effects I would expect to recruit quick. These are the problems with academic sponsored trials since there aren't multiple sites.
Of course they will move Pracinostat into Phase 3. Stock doctor on SA has said this repeatedly. Although I agree with him that data is good enough to do it. I would also argue that the company knows it will be killed if they terminate Pracinostat.
Hmm perhaps a big pharma wants electroporation technology. Pretty big deal considering only other company to do this is Oncosec. Obviously market agrees with me
Funny. I read that persons comment. Like how she said AstraZeneca deal has nothing to do with Oncosec platform even though its electroporation and IL-12.
He didn't even have the guts to ask a question on the earnings call even though he has a lot of questions and confusion about prostate cancer market.